                         SEQUENCE LISTING

<110>  F. Hoffmann-La Roche AG
       Roberts, Christopher R.
       Han, Yeun-Kwei
       Chen, Lin
 
<120>  Insulinotropic peptide synthesis using solid and solution phase 
       combination techniques

<130>  Case 26107

<150>  US 61/174662
<151>  2009-05-01

<160>  15    

<170>  PatentIn version 3.5

<210>  1
<211>  37
<212>  PRT
<213>  Homo sapiens

<400>  1

His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val 
1               5                   10                  15      


Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu 
            20                  25                  30          


Val Lys Gly Arg Gly 
        35          


<210>  2
<211>  31
<212>  PRT
<213>  Homo sapiens

<400>  2

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly 
            20                  25                  30      


<210>  3
<211>  30
<212>  PRT
<213>  Homo sapiens

<400>  3

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 
            20                  25                  30  


<210>  4
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is Aib

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  X is Aib

<400>  4

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg 
            20                  25                  30  


<210>  5
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  amidated Arginine (Argininamide)

<400>  5

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg 
1               5                   10                  


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  6

Ser Tyr Leu Glu Gly 
1               5   


<210>  7
<211>  19
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  amidated Arginine (Argininamide)

<400>  7

Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val 
1               5                   10                  15      


Lys Xaa Arg 
            


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  8

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser 
1               5                   10      


<210>  9
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (30)..(30)
<223>  amidated Arginine (Argininamide)

<400>  9

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa Arg 
            20                  25                  30  


<210>  10
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  10

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Xaa 
1               5                   10              


<210>  11
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  11

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


<210>  12
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  12

Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu 
1               5                   10  


<210>  13
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  13

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu 
            20      


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is Aib

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  amidated Arginine (Argininamide)

<400>  14

Phe Ile Ala Trp Leu Val Lys Xaa Arg 
1               5                   


<210>  15
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Chemically synthesized peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  is substituted by Z being an N-terminal protecting group or 
       hydrogen

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is an achiral amino acid

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  is substituted by B' being a solid phase resin or -OH

<400>  15

Phe Ile Ala Trp Leu Val Lys Xaa 
1               5               


